alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5799 Enrolled Bill (ENR)]

        H.R.5799

                     One Hundred Eighteenth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

         Begun and held at the City of Washington on Wednesday,
         the third day of January, two thousand and twenty-four

                                 An Act

 
 To designate the checkpoint of the United States Border Patrol located 
on United States Highway 90 West in Uvalde County, Texas, as the ``James 
                R. Dominguez Border Patrol Checkpoint''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
    This Act may be cited as the ``James R. Dominguez Memorial Act of 
2023''.
SEC. 2. FINDINGS.
     Congress finds the following:
        (1) A native of San Antonio, Texas, Border Patrol Agent James 
    R. Dominguez--
            (A) proudly and honorably served his country as an agent of 
        the U.S. Border Patrol for more than 12 years;
            (B) began his service with the U.S. Border Patrol in 2000; 
        and
            (C) graduated as part of the 434th session of the Border 
        Patrol Academy.
        (2) Agent Dominguez served at the Uvalde Station in the Del Rio 
    Sector.
        (3) On July 19, 2012, Agent Dominguez stopped to clear debris 
    from the roadway that posed risks to road and community safety 
    along Highway 90 near Cline, Texas. While on scene, Agent Dominguez 
    was struck and killed by a passing vehicle.
        (4) Agent Dominguez is survived by his wife and 4 children.
SEC. 3. DESIGNATION.
    The checkpoint of the United States Border Patrol located on United 
States Highway 90 West in Uvalde County, Texas, shall be known and 
designated as the ``James R. Dominguez Border Patrol Checkpoint''.
SEC. 4. REFERENCES.
     Any reference in a law, map, regulation, document, paper, or other 
record of the United States to the checkpoint described in section 3 
shall be deemed to be a reference to the ``James R. Dominguez Border 
Patrol Checkpoint''.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
```
EXHIBIT 13.1

                       CERTIFICATION OF ART LANG PURSUANT
          TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
                       OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of IMA Exploration  Inc. (the "Company") on
Form 20-F for the year ending  December 31, 2004,  as filed with the  Securities
and Exchange  Commission on the date hereof (the "Report"),  I, Art Lang,  Chief
Financial  Officer and Director of the Company,  certify,  pursuant to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of
2002, that:

     (1)  The Report fully  complies with the  requirements  of section 13(a) or
          15(d) of the Securities  Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.

A signed original of this written statement has been provided to the Company and
will be  retained  by the  Company  and  furnished  to the SEC or its staff upon
request.


/s/  ART LANG
------------------------------------
Art Lang,
Chief Financial Officer and Director
The Honorable Ortrie D. Smith, United States District Judge for the Western

*

District of Missouri, sitting by designation.

United States Court of Appeals

FOR THE EIGHTH CIRCUIT

_____________

No. 97-3452MN

_____________

United States of America, *

*

Appellee, * Appeal from the United States

* District Court for the District

v. * of Minnesota.

*

Edward Boler, * [UNPUBLISHED]

*

Appellant. *

_____________

 Submitted: February 10, 1998

Filed: February 20, 1998

_____________

Before FAGG and MURPHY, Circuit Judges, and SMITH, District Judge. *

_____________

PER CURIAM.

Edward Boler appeals his conviction for possession with intent to distribute

cocaine. On appeal, Boler claims the district court committed error in refusing to

suppress cocaine seized during the follow-up search of Boler's duffle bag. We

disagree. Having reviewed the record and the parties' briefs, we conclude the district

court correctly ruled that Boler impliedly consented to a second search of his duffle

bag. We thus uphold Boler's conviction. See 8th Cir. R. 47B.
-2-

A true copy.

Attest:

CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
1 The Honorable Ann D. Montgomery, United States District Judge for the District of Minnesota. 

## United States Court of Appeals FOR THE EIGHTH CIRCUIT

___________ Nos. 06-4004/07-1177

___________ Dim Njaka, * * Appellant, * * Appeals from the United States v. * District Court for the * District of Minnesota. John E. Potter, Postmaster General, * United States Postal Service, * [UNPUBLISHED] * Appellee. *

___________ Submitted: June 10, 2008 Filed: June 13, 2008

___________ Before MURPHY, COLLOTON, and SHEPHERD, Circuit Judges.

___________ PER CURIAM. In these consolidated appeals, Dim Njaka appeals the district court’s 1 dismissal of his employment-discrimination action an d the court’s denial of his motion for reconsideration. Having carefully revi ewed the parties’ arguments and the submissions on appeal, we find no basis for re versal. Accordingly, we affirm. See 8th Cir. R. 47B. The pending motions are denied.
# United States Court **of Appeals**  **f or the Fifth Circuit** 

**____________** No. 22 - 51093 Summary Calendar

**____________ United States of America,**  Plaintiff
— Appellee **,** versus **Ever Sanchez -**  **Herrera,** Defendant
— Appellant **.**

**______________________________** Appeal from the United States District Court for the Western District of Texas USDC No. 3:22 - CR - 1230 - 1

**_________________ _____________**  Before **Davis, Duncan,** and **Engelhardt,** Circuit Judges **. Per Curiam**  **:** ***** Ever Sanchez - Herrera appeals his conviction and sentence for illegal reentry after removal in violation of 8 U.S.C. § 1326(a) and (b)(1). In his sole issue on appeal, Sanchez - Herrera contends that § 1326(b) is unconstitutional because it permits a sentence above the otherwise - applicable statutory

**_____________________** * This opinion is not designated for publication. See **5th Cir .**  **R .**  47.5. United States Court of Appeals Fifth Circuit 

### FILED June 15, 2023 Lyle W. Cayce Clerk Case: 22-51093 Document: 00516788695 Page: 1 Date Filed: 06/15/2023No. 22 - 51093

2 maximum based on facts that were neither alleged in the indictment nor found by a jury beyond a reasonable doubt. He has filed an unopposed motion for summary disposition and a letter brief explaining that he has raised this issue only to preserve it for further review and correctly conceding that this issue is foreclose d by Almendarez - Torres v. United States , 523 U.S. 224 (1998). See United States v. Pervis , 937 F.3d 546, 553 - 54 (5th Cir. 2019). Because summary disposition is appropriate, see Groendyke Transp., Inc. v. Davis , 406 F.2d 1158, 1162 (5th Cir. 1969), Herrer a - Sanchez’s motion is **GRANTED** , and the district court’s judgment is **AFFIRMED** . Case: 22-51093 Document: 00516788695 Page: 2 Date Filed: 06/15/2023
EXHIBIT 10.1


ARRAY BIOPHARMA
INC.


DESCRIPTION OF
PERFORMANCE BONUS PROGRAM


Array BioPharma Inc. (the
“Company”) has established an annual performance bonus program for employees,
including the Company’s executive officers. Through this program, employees can
receive an annual bonus payable in cash, stock or stock option equivalents
based on achievement of key Company and individual goals.  There is no
guarantee that bonuses will be awarded in any given year. The bonus program is
intended to strengthen the connection between individual compensation and
Company success; reinforce the Company’s pay-for-performance philosophy by
awarding higher bonuses to higher performing employees; and help ensure that
the Company’s cash compensation is competitive.


At the beginning of the
fiscal year, the Compensation Committee establishes the minimum, target and
stretch corporate performance goals, and the relative weighting of these goals,
for the upcoming fiscal year. The goals generally are based on the following
objective performance criteria: revenues, earnings per share, year-end cash,
clinical development goals with respect to the Company’s proprietary drug
programs and transactional goals relating to out-licensing transactions. Each
participant in the bonus program may be eligible to receive a target bonus
amount calculated by multiplying the participant’s base salary by a percentage
value later assigned to the participant or his or her position with the Company
by the Compensation Committee.


Following the end of each
fiscal year, the Compensation Committee determines in its discretion the extent
to which the company-wide and individual performance goals were attained. Based
on this assessment, the Compensation Committee will award bonuses equal to a
varying percentage of an employee’s target bonus amount. The Compensation
Committee may award a bonus in an amount less than or greater than the amount
earned by a participant under the bonus program.


Individual bonuses can
vary significantly based on performance. Any bonuses for a particular year are
paid as a lump sum cash award, less applicable payroll and other withholdings,
in the quarter following that year. The plan can be amended in whole or in part
but the compensation committee at any time until paid.


*****
<PAGE>

                                                       Exhibit 10(ao)
                                                       Form 10-K for 1996
                                                       File No. 1-11237



                                  AT&T Capital
                                  ------------

Amendment Number 2  1996 AT&T Capital Corporation Leadership
                    ----------------------------------------

                           Severance Plan
                           --------------

          The 1996 AT&T Capital Corporation Leadership Severance Plan (the
"Plan") is hereby amended as set forth below:

     1.   Section 1(1) of the Plan is amended by inserting the following new
sentence after the first sentence of the section:

     "No person who becomes employed by the Company or any Subsidiary on or
after January 17, 1997, shall be eligible to participate in the Plan."



<PAGE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Government Accountability Office

# AGENCY:

U.S. Government Accountability Office (GAO).

# ACTION:

Request for letters of nomination and resumes.

# SUMMARY:

The Medicare Access and CHIP Reauthorization Act of 2015 established the Physician-Focused Payment Model Technical Advisory Committee to provide comments and recommendations to the Secretary of Health and Human Services on physician payment models and gave the Comptroller General responsibility for appointing its members. GAO is now accepting nominations of individuals for this committee.

# DATES:

Letters of nomination and resumes should be submitted no later than July 16, 2021, to ensure adequate opportunity for review and consideration of nominees prior to appointment. Appointments will be made in October 2021.

# ADDRESSES:

Submit letters of nomination and resumes to *PTACcommittee@gao.gov*.

# FOR FURTHER INFORMATION CONTACT:

Greg Giusto at (202) 512-8268 or *giustog@gao.gov* if you do not receive an acknowledgement within a week of submission or you need additional information. For general information, contact GAO's Office of Public Affairs at (202) 512-4800.

Authority:Sec. 101(e), Pub. L. 114-10, 129 Stat. 87, 115 (2015).

Gene L. Dodaro,

Comptroller General of the United States.

[FR Doc. 2021-12145 Filed 6-11-21; 8:45 am]

BILLING CODE 1610-02-P
#### Gregory R. BOZE and Sheryl Boze, Appellants, v. COUNTY OF MACON, Missouri and Stephen E. Petre, Respondents.

No. WD 45677.

Missouri Court of Appeals, Western District.

Feb. 9, 1993.

Motion for Rehearing and/or Transfer to Supreme Court Denied March 30, 1993.

Application to Transfer Denied May 25, 1993.

Charles A. Powell, Jr., Macon, for appellants Gregory R. and Sheryl Boze.

Gerald E. Roark, Hendren and Andrae, Jefferson City, for respondent County of Macon, Missouri.

Jeffrey O. Parshall and Susan Ford Robertson, Knight, Ford, Wright, Atwill, Pars-hall & Baker, Columbia, for respondent Pe-tre.

Before BERREY, P.J., and ULRICH and SMART, JJ.

ORDER

PER CURIAM.

Plaintiffs Gregory R. Boze and Sheryl Boze appeal from a jury verdict for defendants in a case arising out of a collision between a vehicle driven by Mr. Boze and a road grader operated by an employee of Macon County.

Judgment affirmed. Rule 84.16(b).
Consulting Agreement, between Kana Software, Inc. and William T. Clifford



 EXHIBIT 10.01 
 CONSULTING AGREEMENT 
 This Agreement is made and entered into as of
October 30, 2006 (the “Effective Date”) by and between Kana Software, Inc., a Delaware corporation (the “Company”), and William T. Clifford (the “Consultant”). 

R E C I T A L S 
 A. The Company desires to engage the Consultant to advise management in the operation of the Company and in the Company’s strategic plans. 
 NOW, THEREFORE, the parties hereto hereby agree as follows: 
 1. Appointment of Consultant. The Company hereby appoints Consultant as a consultant to the Company, to advise the Company’s management on the Company’s strategic planning and business (in addition to
his role as a member of the Board of Directors of the Company), and the Consultant hereby accepts such appointment. From time to time during the term of this Agreement, Consultant shall provide the Company with strategic advice through direct
consultation, participation in meetings, telephone calls, presentations, electronic mail and/or other means. 
 2. Term.
Consultant’s appointment shall be for a period of twelve (12) months commencing January 24, 2006, and will expire upon expiration of such twelve (12) month period, unless renewed in a writing signed by both parties; provided,
however, that either party hereto may terminate such appointment earlier, at any time and with or without cause, on ten days written notice to the other party. The period during which the Consultant’s appointment is in effect shall
hereinafter be referred to as the “Agreement Term”. 
 3. Fee. Consultant shall be paid a fee of $59,900 in
consideration for Consultant’s services, payable up front, for the period commencing January 24, 2006, until January 23, 2007. 
 4.
Independent Contractor. Consultant is an independent contractor of the Company and not an employee. 
 5. Notice. Any notice
required or permitted hereunder may be given by certified mail, return receipt requested, or by express mail, to the party to whom it is to be given at the address set forth below such party’s signature to this Agreement, and if so given shall
be deemed given on the day mailed. 
 6. Governing Law. This Agreement shall be governed by, and construed in accordance with, the law
of the State of California, excluding that body of law relating to conflicts of law. 
 7. Entire Agreement. This Agreement
constitutes the full and complete understanding and agreement of the parties hereto with respect to the subject matter hereof and supersedes any and all prior understandings and agreements of the parties with respect to the same subject matter,
whether oral or written. This Agreement can only be amended if set forth in writing in a document signed by the parties hereto. 







 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

  

			
	 KANA SOFTWARE, INC.

		
	 By:
	 	 /s/ John M. Thompson
  

		 	     John M. Thompson

		 	     Chief Financial Officer
     181 Constitution Drive
     Menlo Park, CA 94025

	
	 CONSULTANT

		
		 	 /s/ William T. Clifford
  

		 	     William T. Clifford
[Federal Register Volume 60, Number 74 (Tuesday, April 18, 1995)]
[Notices]
[Page 19403]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-9469]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Round Table Discussion of the Vessel Sanitation Program's 
``Shipbuilding Construction Guidelines for Vessels Destine To Call on 
U.S. Ports''--Public Meeting

    The National Center for Environmental Health (NCEH) of the Centers 
for Disease Control and Prevention (CDC) announces the following 
meeting:

    Name: Round Table Discussion of the Vessel Sanitation Program's 
(VSP) ``Shipbuilding Construction Guidelines for Vessels Destine to 
Call on U.S. Ports''--Public meeting between CDC, the cruise ship 
industry, and other interested parties.
    Times and Dates: 9 a.m.-5 p.m., May 18, 1995. 9 a.m.-1 p.m., May 
19, 1995, if necessary.
    Place: NCEH, CDC, Chamblee Facility, Building 101, Third Floor 
Conference Room, 4770 Buford Highway, N.E., Atlanta, Georgia 30341-
3724, telephone 404/488-7070.
    Status: The meeting will be open to the public for 
participation, comment, and observation, limited only by space 
available. The meeting room will accommodate approximately 35 
people.
    Purpose: To obtain individual comments and information for 
further developing the VSP's shipbuilding construction guidelines, 
and to discuss the VSP's experience to date with construction 
inspections at shipyards.
    Matters to be Discussed: The VSP offers consultative services 
that include reviewing plans for renovations and new construction of 
cruise ships. The VSP staff conduct construction inspections when a 
ship is near completion or when it first enters a U.S. port for 
compliance with VSP sanitation criteria. The VSP has drafted 
shipbuilding construction guidelines for use when conducting 
construction inspections. This public meeting is to obtain technical 
and general comments and information from the cruise ship industry 
and other interested parties regarding the VSP's draft 
``Shipbuilding Construction Guidelines for Vessels Destine to Call 
on U.S. Ports.''
    Contact Person for More Information: Thomas E. O'Toole, Deputy 
Chief, Special Programs Group (F29), NCEH, CDC, 4770 Buford Highway, 
NE, Atlanta, Georgia 30341-3724, telephone 404/488-7073.

    Dated: April 12, 1995.
Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 95-9469 Filed 4-17-95; 8:45 am]
BILLING CODE 4163-18-M
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-850]
 AGENCY: Drug Enforcement Administration, Justice.
 ACTION: Notice of application.
 SUMMARY: Usona Institute has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
 DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 14, 2021. Such persons may also file a written request for a hearing on the application on or before July 14, 2021.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 10, 2021, Usona Institute, 2780 Woods Hollow Road, Room 2412, Fitchburg, Wisconsin 53711-5370, applied to be registered as an importer of the following basic class(es) of controlled substance(s): Controlled substance
Drug code
Schedule5-Methoxy-N-N-dimethyltryptamine
7431
IDimethyltryptamine
7435
IPsilocybin
7437
IPsilocyn
7438
I
 The institute plans to import the listed controlled substances to be used for research and analytical purposes. The materials will not be used for clinical trials or bulk manufacture. No ( print page 31538)other activity for these drug codes is authorized for this registration. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. William T. McDermott, Assistant Administrator.


[FR Doc. 2021-12353 Filed 6-11-21; 8:45 am] BILLING CODE P